Sahajanand Medical Technologies (SMT), a global leader in cardiovascular solutions, has introduced the Hydra™ Transcatheter Aortic Valve Implantation (TAVI) system in Russia. The device offers a minimally invasive treatment for severe aortic stenosis, particularly for patients unsuitable for open-heart surgery.

Growing Demand for TAVI in Russia

The adoption of TAVI procedures in Russia continues to rise, addressing the needs of a growing population of patients with severe aortic stenosis. Hydra™ has been developed to cater specifically to this demand, highlighting SMT’s focus on advancing healthcare through innovative technologies.

Features of the Hydra™ TAVI System

The Hydra™ system is designed to enhance precision and safety during aortic valve replacement procedures. Key features include:

• Adaptability for Precise Placement: The device can be re-sheathed, re-positioned, and retrieved, allowing for accurate placement.
• Supra-Annular Valve Design: This configuration improves blood flow dynamics for better outcomes post-procedure.
• Deployment Markers: Integrated frame markers guide accurate valve positioning.
• Enhanced Safety: A sealing skirt reduces paravalvular leaks, and the stent frame design minimises impact on the heart's conduction system.
• Future Coronary Access: An open-cell design simplifies access to coronary arteries for future interventions.

Regulatory Approval

The Hydra™ system has received approval from Roszdravnadzor, the regulatory authority responsible for medical device oversight in Russia. Meeting these stringent requirements underlines the system’s safety and effectiveness.

Strengthening SMT’s Presence in Russia

The launch of Hydra™ marks SMT’s expansion into structural heart disease treatments in Russia, building on the success of the Supraflex Cruz™ drug-eluting stent system. This development supports SMT’s mission to deliver advanced cardiovascular care globally while meeting the unique needs of high-risk patients in Russia.



Source: smtpl.com

Report Abuse